{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:59:57Z","timestamp":1759694397683},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.mehy.2018.06.020","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T05:23:33Z","timestamp":1529472213000},"page":"68-73","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by \u201cfilling the flap\u201d region of plasmepsin enzymes"],"prefix":"10.1016","volume":"118","author":[{"given":"Ardavan","family":"Abiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mehy.2018.06.020_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.mehy.2018.06.020_b0010","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/med.21340","article-title":"Curious discoveries in antiviral drug development: the role of serendipity","volume":"35","author":"Clercq","year":"2015","journal-title":"Med Res Rev"},{"issue":"11","key":"10.1016\/j.mehy.2018.06.020_b0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"109","key":"10.1016\/j.mehy.2018.06.020_b0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mehy.2017.10.016","article-title":"Artesunate-quercetin\/luteolin dual drug nanofacilitated synergistic treatment for malaria: a plausible approach to overcome artemisinin combination therapy resistance","volume":"1","author":"Puttappa","year":"2017","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.020_b0025","first-page":"52","article-title":"Malaria","volume":"46","author":"Walker","year":"2018","journal-title":"Med Elsevier"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.020_b0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12943-016-0552-0","article-title":"Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis","volume":"15","author":"Conley-LaComb","year":"2016","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.mehy.2018.06.020_b0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pharmthera.2010.08.009","article-title":"Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil\u2122) and potential of other CXCR4 antagonists as stem cell mobilizers","volume":"128","author":"De Clercq","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2018.06.020_b0040","article-title":"The role of CXCL12 in tumor microenvironment","author":"Meng","year":"2017","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.020_b0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.mehy.2018.06.020_b0050","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1016\/j.bmc.2014.05.003","article-title":"Synthesis and antimalarial activity of metal complexes of cross-bridged tetraazamacrocyclic ligands","volume":"22","author":"Hubin","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"13","key":"10.1016\/j.mehy.2018.06.020_b0055","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/jm5014133","article-title":"Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors: miniperspective","volume":"58","author":"Huizing","year":"2015","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.mehy.2018.06.020_b0060","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/med.20082","article-title":"Plasmepsins as potential targets for new antimalarial therapy","volume":"26","author":"Ersmark","year":"2006","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/j.mehy.2018.06.020_b0065","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1074\/jbc.M409740200","article-title":"The role of Plasmodium falciparum food vacuole plasmepsins","volume":"280","author":"Liu","year":"2005","journal-title":"J Biol Chem"},{"issue":"6362","key":"10.1016\/j.mehy.2018.06.020_b0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.aan1478","article-title":"Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion","volume":"358","author":"Nasamu","year":"2017","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.mehy.2018.06.020_b0075","doi-asserted-by":"crossref","first-page":"e1001897","DOI":"10.1371\/journal.pbio.1001897","article-title":"Inhibition of Plasmepsin V activity demonstrates its essential role in protein export, PfEMP1 display, and survival of malaria parasites","volume":"12","author":"Sleebs","year":"2014","journal-title":"PLoS Biol"},{"issue":"2\u20133","key":"10.1016\/j.mehy.2018.06.020_b0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0014-5793(02)02241-X","article-title":"Activity and inhibition of plasmepsin IV, a new aspartic proteinase from the malaria parasite, Plasmodium Falciparum","volume":"513","author":"Wyatt","year":"2002","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.020_b0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-2836(03)00036-6","article-title":"Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum","volume":"327","author":"Asojo","year":"2003","journal-title":"J Mol Biol"},{"issue":"95","key":"10.1016\/j.mehy.2018.06.020_b0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejmech.2015.03.049","article-title":"New paradigm of an old target: An update on structural biology and current progress in drug design towards plasmepsin II","volume":"5","author":"Dan","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.mehy.2018.06.020_b0095","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/prot.24855","article-title":"Flap flexibility amongst plasmepsins I, II, III, IV, and V: sequence, structural, and molecular dynamics analyses","volume":"83","author":"McGillewie","year":"2015","journal-title":"Proteins: Struct Funct Bioinf"},{"key":"10.1016\/j.mehy.2018.06.020_b0100","unstructured":"LigPrep, Schr\u00f6dinger, LLC, New York, NY; 2018."},{"key":"10.1016\/j.mehy.2018.06.020_b0105","unstructured":"Molecular Operating Environment (MOE). 2015.10. Chemical Computing Group ULC. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7; 2018."},{"key":"10.1016\/j.mehy.2018.06.020_b0110","unstructured":"https:\/\/www.rcsb.org\/structure\/1LF4."},{"issue":"7","key":"10.1016\/j.mehy.2018.06.020_b0115","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.mehy.2018.06.020_b0120","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.mehy.2018.06.020_b0125","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212 ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.mehy.2018.06.020_b0130","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbapap.2016.06.019","article-title":"The prosegment catalyzes native folding of Plasmodium falciparum plasmepsin II","volume":"1864","author":"Jaafar","year":"2016","journal-title":"Biochim Biophy (BBA)-Proteins Proteomics"},{"key":"10.1016\/j.mehy.2018.06.020_b0135","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2015.00276","article-title":"AMD3100\/CXCR4 inhibitor","volume":"6","author":"De Clercq","year":"2015","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.mehy.2018.06.020_b0140","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1021\/bi0117549","article-title":"Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target","volume":"41","author":"Nezami","year":"2002","journal-title":"Biochemistry"},{"issue":"13","key":"10.1016\/j.mehy.2018.06.020_b0145","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1021\/jm040884n","article-title":"Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II","volume":"48","author":"Johansson","year":"2005","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.mehy.2018.06.020_b0150","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1128\/AAC.45.9.2577-2584.2001","article-title":"New class of small nonpeptidyl compounds blocksplasmodium falciparum development in vitro by inhibiting plasmepsins","volume":"45","author":"Jiang","year":"2001","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718303785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718303785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T02:17:01Z","timestamp":1534817821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987718303785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"alternative-id":["S0306987718303785"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2018.06.020","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by \u201cfilling the flap\u201d region of plasmepsin enzymes","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2018.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}